This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shobokshi, A. Articles by Shaarawy, M. Search for Related Content PubMed PubMed Citation Articles by Shobokshi, A. Articles by Shaarawy, M. Social Bookmarking                   What's this?

Correction of Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome By Combined Rosiglitazone and Clomiphene Citrate Therapy

Mohamed Shaarawy, PhD, FRCPath

Department of Obstetrics and Gynecology, Faculty of Medicine, King Abdul-Aziz University, Jeddah, Saudi Arabia; Department of Obstetrics and Gynecology, (Endocrinology and Maternal Biochemistry Unit), Faculty of Medicine, Cairo University, Cairo, Egypt

Objective: To investigate the effects of combined rosiglitazone and clomphene citrate versus clomiphene citrate monotherapy on serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels in polycystic ovary syndrome (PCOS) and to evaluate these therapeutic interventions in the link between hyperinsulinemia and hormonal perturbations in PCOS.

Methods: We performed a randomized clinical study at the King Abul-Aziz and Cairo University Hospitals. We studied 50 women with PCOS. Clinical diagnosis was based on hyperandrogenism; hyperinsulinism; oligomenorrhea; or amenorrhea, anovulatory cycles, and ultrasonographic findings. They were randomly assigned to two groups of 25 women each. One group was treated with rosiglitazone and clomiphene citrate; the other was treated only with clomphene citrate. Serum concentrations of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, dehydroepiandrosterone sulfate (DHEAS), free testosterone, IGF-1, and IFGBP-3 were measured by specific radioimmunoassays before and after treatment.

Results: Combined rosiglitazone and clomphene treatment led to a significant reduction in area under the insulin curve (AUG insulin), whereas clomphene monotherapy did not lead to this reduction. Both types of treatment induced a significant decrease in LH, LH:FSH ratio, free testosterone, and IGF1:IGBP-3 ratio and were associated with a significant increase in IGFBP-3 levels. These changes were more pronounced in PCOS patients treated with combined rosiglitazone and clomiphene than in those treated with clomiphene monotherapy. Regular menstrual cycles occurred in 72% of the former group and 48% of the latter.

Conclusion: Combined rosiglitazone and clomiphene was an effective therapeutic regimen for correcting insulin resistance in patients with PCOS, possibly by reducing IGF1 bioavailability to the ovaries, thus modifying the hyperandrogenic intrafollicular milieu that occurs in PCOS. In addition, the clinical and hormonal responses were better than with clomiphene alone.

Key Words: Insulin-like growth factor-1 • insulin-like growth factor binding protein-3 • polycystic ovary syndrome • rosiglitazone • clomiphene citrate

Journal of the Society for Gynecologic Investigation, Vol. 10, No. 2, 99-104 (2003)
DOI: 10.1016/S1071-55760200260-5


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?